←
Alexander Drilon MD172 posts
Alexander Drilon MD avatar

Alexander Drilon MD

@alexdrilon

Chief, Early Drug Development Service; Associate Attending Physician, Thoracic Oncology Service; Memorial Sloan Kettering Cancer Center

◷ Joined October 2011▧ 25 Photos and videos
Alexander Drilon MD avatar
Alexander Drilon MD@alexdrilon·4 Jun 2024

In the era of Project Optimus, expeditiousness needs to be preserved for dose finding in rare cancers. Common cancers now contain multiple rare genomic and proteomic subsets, underscoring the importance of this mindset. @YoninaMG @AlexiaIasonos

Now online in @CD_AACR, a special commentary for #ASCO24: Optimus-Era Dose Finding for Rare Cancers - by @YoninaMG, Sean Devlin, @AlexiaIasonos, and @alexdrilon doi.org/10.1158/2159-8290.CD… @MSKCancerCenter

Post attachmentPost attachment
Alexander Drilon MD avatar
Alexander Drilon MD@alexdrilon·16 Nov 2023

Repotrectinib is FDA approved for ROS1+ lung cancers in the TKI naive and pretreated settings. Many thanks to the patients, advocates, and study teams around the world who made this possible. onclive.com/view/fda-approve…

Alexander Drilon MD avatar
Alexander Drilon MD@alexdrilon·10 Jun 2023

Don’t miss out on the opportunity to join the lab of the fabulous Dr. Misale. Our phase I team is absolutely excited to continue working with her. Congratulations @Sandra_Misale!!

I have some news, I'm thrilled to announce that the Misale Lab will open in July at @hopkinskimmel @HopkinsMedicine! We will work on resistance to therapy in solid tumors and we are hiring. Join us in this journey! #newPI #LabLaunch #cancer #kras #targetedtherapies #WomenInSTEM

Alexander Drilon MD avatar
Alexander Drilon MD@alexdrilon·3 Jun 2023

Breaking tradition can improve patient outcomes. In novel-known combinations where the novel drug is unlikely to work well alone, prolonged exposure to monotherapy in dose escalation is not patient-centric. This alternative FDA-approved phase I design poses a potential solution.

Post attachment

Just published: #SHP2 Inhibition Sensitizes Diverse Oncogene-addicted Solid Tumors to Re-treatment with Targeted Therapy by @alexdrilon S. Michael Rothenberg and colleagues @MSKCancerCenter @PfizerOncMed. bit.ly/45HB06K #ASCO23

Post attachment
Sandra Misale avatar
⟳ Alexander Drilon MD retweeted
Sandra Misale@Sandra_Misale·10 Nov 2022

Out today in @CD_AACR our new work where we describe the genetic bases of acquired resistance to EGFR/KRAS G12C dual blockade in colorectal cancer. Here’s the link of the paper shorturl.at/EOPT8 and a thread👇:

Alexander Drilon MD avatar
Alexander Drilon MD@alexdrilon·3 May 2022

Excellent work from the Klebanoff lab on TCR development for an HLA-A*03:01 restricted public neoantigen generated in the context of a PIK3CA H1047L catalytic subunit hotspot mutation. rdcu.be/cMjvb

A high-throughput platform to find rare #Tcells that recognize shared cancer #neoantigens identifies TCRs specific for a conserved and therapeutically actionable epitope in mutant PIK3CA, a common driver oncogene @KlebanoffLab @MSKCancerCenter @parkerici nature.com/articles/s41591-0…

Alexander Drilon MD avatar
Alexander Drilon MD@alexdrilon·18 Mar 2022

RETi resistance in lung, thyroid & other cancers can be complex. This paper includes insights into the serial kinetics of resistance acquisition, the potential emergence of RET wild type populations & the frequency of polyclonal resistance. Proud to be part of this team!

This tweet is unavailable

Alexander Drilon MD avatar
Alexander Drilon MD@alexdrilon·6 Feb 2022

The first publication of larotrectinib in NTRK fusion+ lung cancers alone is out. Beyond the initial systemic & intracranial response gains, the ~35 month median PFS and the ~41 month median OS impress. Wonderful news for patients, advocates, and providers across the world.

.@alexdrilon et al. report on first analysis of the efficacy & safety of larotrectinib in pts with TRK fusion–positive lung cancer from a registrational data set. ORR of 73% ub 15 evaluable pts w OS of 40.7 months. Larotrectinib was well tolerated. fal.cn/3lTFs

Post attachment
Alison Schram avatar
⟳ Alexander Drilon MD retweeted
Alison Schram@AliSchram·4 Jun 2021

Quick recap of today's presentation of Zeno in heavily pretreated NRG1+ solid tumors. Efficacy observed across tumor types with ORR of 42% in PDAC. Thanks to @ASCO for the opportunity to present, @GarridoLagunaMD for an excellent discussion, collaborators, and patients. #ASCO2021

Post attachmentPost attachmentPost attachmentPost attachment
Alison Schram avatar
⟳ Alexander Drilon MD retweeted
Alison Schram@AliSchram·4 Jun 2021

I’m honored to be among the #ConquerCancer Grant & Award Class of 2021 (CDA) and 2018 (YIA). Donors make these research opportunities possible. Give to the @ASCO CONQUERS CANCER Fund to help fuel the next generation of researchers https://t.co/zwZIF01Ujp #ASCO21

Retweet this #ASCO21 #ConquerCancer collage and tag the doctors you see! Your gift to the #ASCOCONQUERSCANCER Fund supports Grant & Award recipients from around the globe 🌍🌎🌏 https://t.co/NUvFdWLWY7

Post attachment
RETpositive avatar
⟳ Alexander Drilon MD retweeted
RETpositive@RETpositive·19 Apr 2021

RETpositive has officially launched! We are a patient-led coalition formed to advance research on RET+ cancers. Through our partnership with @LUNGevity and a generous donation-matching program, we hope to fund lifesaving research. Join us at retpositive.org #RETcancer

Post attachment